PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

IntroductionImmune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune−related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with aut...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. Fründt, Ansgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-01-01
Col·lecció:	Frontiers in Immunology
Matèries:	autoimmune disease (AID) immune checkpoint inhibitors (ICI) autoimmune liver diseases (AILD) immune related adverse effects (irAEs) PD-1/PD-L1 immune checkpoint inhibitors autoimmune hepatitis (AIH)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1326078/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!